The Neuroprotective Effects of Dexmedetomidine During Brain Surgery
Status:
Completed
Trial end date:
2020-04-14
Target enrollment:
Participant gender:
Summary
Dexmedetomidine (DEX) is a Alpha-2 specific agonist, is a common ICU sedation medication. In
brain tumor resection craniotomy, it is proven to be effective in improving postoperative
hypertension and tachycardia, mitigates postoperative nausea and vomiting and relives
postoperative pain. In addition, many animal experiments show that DEX inhibits the
proapoptosis in the mitochondrial in vivo and therefore avoids neuronal injury. It is also
reported to be neuroprotective to isoflurane-induced neurotoxicity and to improve cerebral
focal ischemic region (penumbra). However, the neuroprotective effects were never
investigated clinically in patients undergoing brain tumor resection surgery.